Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2026 Sep 11;17:1974800. doi: 10.3389/fimmu.2026.1974800

Correction: Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1

Ines Zettl 1,‡, Isabella Ellinger 1, Mohammed Zghaebi 2, Sarah Jance 1, Vanessa Izewski 1, Anja Drescher 3, Heimo Breiteneder 1, Manuel Röck 4, Martin Tollinger 4, Julia Eckl-Dorna 2, Sergei V Tillib 5,†, Sabine Flicker 1,*,†
PMCID: PMC13613330  PMID: 42798949

Reference 49 “Melnikova DN, Potapov AE, Ovchinnikova TV, Bogdanov IV. Modeling human airway epithelial barrier penetration using birch Bet v 1 and alder Aln g 1 pollen allergens during sensitization process. Int J Mol Sci. (2025) 26:5169. doi: 10.3390/ijms26115169” was not cited in the article. The citation has now been inserted in the section Discussion, paragraph 4 and should read:

“This internalisation behavior aligns with recent insights into Bet v 1-epithelial interactions, providing the first evidence that Bet v 1 can actively penetrate healthy respiratory cell epithelial monolayers (49).”

Consequently, the sequence of all subsequent references has been changed as shown below:

“Synthetic nanobody libraries take the nanobody scaffold and introduce highly diverse com plementarity-determining loops, thereby simulating the clonal diversity of an individual (50). Taking it one step further, a recent publication introduced a novel technology called BindCraft, which uses the protein structure model AlphaFold2 to predict, design, optimize and filter de novo binders (51).”

“This example successfully illustrates the development of a blocking, allergen-specific binder without relying on animal use or a high throughput screening process of the respective library (51).”

“The latter may include tandem-linked nanobodies targeting different epitopes on the same antigen or post-translational multimerization of the current bispecific building block (46, 52).”

“It is known that besides paracellular penetration due to epithelial barrier damage (21, 53, 54), transcytosis is also an important factor in the uptake of Bet v 1 (15, 16, 55).”

“The key advantages of a local approach including rapid onset, reduced systemic exposure and hence reduced severe side effects, have already been acknowledged and led to development of first nanobodies for inhaled delivery tested in preclinical models (56, 57).”

“Recent data indicates that Bet v 1 can induce a transcriptional of alarmins like IL-33 in airway epithelium contributing to transcellular penetration (49).”

Footnotes

Edited and reviewed by: Mario Sergio Palma, São Paulo State University, Brazil

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES